REN and diabetic kidney disease: In a phase II clinical trial in patients with moderate to advanced diabetic nephropathy receiving renin–angiotensin system blockade (mean eGFR 35.5 mL/min/m2; mean UPCR 3.3 g/gCr), the participants were scheduled to receive a placebo or 2, 10, or 50 mg of LY2382770 monthly dosing for 12 months.